{"product_id":"drio-vrio-analysis","title":"DarioHealth Corp. (DRIO): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to DarioHealth Corp. (DRIO)'s enduring success: this VRIO Analysis cuts straight to the core, revealing exactly which of its resources are truly Valuable, Rare, Inimitable, and Organized for maximum competitive advantage. The distilled findings in \u0026amp;O4\u0026amp; offer a powerful snapshot - click below to explore the full strategic breakdown and see how DarioHealth Corp. (DRIO) sustains its market edge.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eDarioHealth Corp. (DRIO) - VRIO Analysis: 1. AI-Driven Data \u0026amp; Personalization Engine\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core asset for DarioHealth Corp. (DRIO) right now: their data engine. This isn't just about collecting numbers; it’s about turning those numbers into demonstrable financial and clinical wins for their clients. That's where the real value lies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Personalized Care Driving Measurable Results\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe platform’s value proposition hinges on its ability to personalize care using massive datasets. DarioHealth is actively leveraging over \u003cstrong\u003e13 billion\u003c\/strong\u003e proprietary user data points to refine its clinical services and guide user navigation. This personalization translates directly into hard outcomes that payers and employers care about. For instance, published data shows users achieving a \u003cstrong\u003e1.4%\u003c\/strong\u003e reduction in eHbA1c and an average \u003cstrong\u003e10%\u003c\/strong\u003e Body Mass Index (BMI) reduction. Furthermore, a study with Sanofi demonstrated an estimated \u003cstrong\u003e$5,077\u003c\/strong\u003e in medical cost savings per user annually. When you see non-GAAP gross margins on B2B2C contracts hitting \u003cstrong\u003e80%+\u003c\/strong\u003e, you know the service is sticky and delivering ROI, which they estimate at around \u003cstrong\u003e5x\u003c\/strong\u003e for payers.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Depth of Longitudinal Data\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHonestly, the sheer volume and longitudinal nature of this real-world data set is what sets it apart in the digital health space. It’s not just a snapshot; it’s years of accumulated, multi-condition data spanning diabetes, hypertension, and more. This depth is something new entrants simply cannot replicate overnight. It’s a genuine data moat.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: High Barrier to Entry\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eReplicating this specific, deep dataset, along with the proprietary AI models trained on it, would require significant time and capital investment - we are talking years and hundreds of millions, given the history of development in this sector. The combination of the data and the algorithms that interpret it creates a high barrier. It’s not just about buying software; it’s about owning the learning curve.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Executing the AI Transformation\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eYes, DarioHealth is definitely organizing around this asset. They are in the middle of a comprehensive AI transformation to automate workflows and scale efficiently. This isn't just talk; they are seeing results, having already achieved a \u003cstrong\u003e$17.2 million\u003c\/strong\u003e, or \u003cstrong\u003e31%\u003c\/strong\u003e, reduction in operating expenses for the first nine months of 2025 compared to the prior year period. They expect an additional \u003cstrong\u003e15–20%\u003c\/strong\u003e reduction in operating expenses as the AI implementation matures. This focus on cost reduction and scalability shows they are structuring the business to maximize the data advantage.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe advantage here is set to be sustained. Every new user interaction feeds the engine, deepening the data moat and making it increasingly difficult for competitors to catch up. With \u003cstrong\u003e79\u003c\/strong\u003e new employer clients signed year-to-date in 2025, surpassing their target by \u003cstrong\u003e98%\u003c\/strong\u003e, the data flywheel is spinning faster, solidifying their position.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on how this engine scores:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n    \u003ctd\u003eAssessment\u003c\/td\u003e\n    \u003ctd\u003eScore (Y\/N)\u003c\/td\u003e\n    \u003ctd\u003eImplication\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eDrives measurable cost savings (e.g., $5,077\/user\/year) and clinical improvements (e.g., 1.4% eHbA1c reduction)\u003c\/td\u003e\n    \u003ctd\u003eY\u003c\/td\u003e\n    \u003ctd\u003eCompetitive Parity or Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003ePossession of 13B+ proprietary, longitudinal, multi-condition data points\u003c\/td\u003e\n    \u003ctd\u003eY\u003c\/td\u003e\n    \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eHigh cost and time required to replicate the dataset and trained AI models\u003c\/td\u003e\n    \u003ctd\u003eY\u003c\/td\u003e\n    \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eActively implementing AI for cost reduction (targeting 15-20% further OpEx cut) and scaling\u003c\/td\u003e\n    \u003ctd\u003eY\u003c\/td\u003e\n    \u003ctd\u003eExploiting Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the execution risk in converting the Q3 2025 revenue of $\u003cstrong\u003e5.0 million\u003c\/strong\u003e into consistent growth, though the pipeline looks strong.\u003c\/p\u003e\n\n\u003cp\u003eKey organizational focus areas supporting this asset include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDriving multi-condition adoption (over \u003cstrong\u003e50%\u003c\/strong\u003e of new clients choose multi-condition).\u003c\/li\u003e\n\u003cli\u003eAchieving high gross margins on recurring revenue, with non-GAAP B2B2C margins over \u003cstrong\u003e80%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eReducing operating expenses through AI automation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eDarioHealth Corp. (DRIO) - VRIO Analysis: 2. Integrated Multi-Condition Digital Therapeutics Platform\n\u003c\/h2\u003e\n\u003cp\u003e\nDario addresses 5 chronic conditions on a single unified platform.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCondition Addressed by Dario\u003c\/th\u003e\n\u003cth\u003eTypical Competitor Coverage\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiabetes\u003c\/td\u003e\n\u003ctd\u003e1–3 conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHypertension\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeight Management\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMusculoskeletal (MSK)\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBehavioral Health\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nThe platform addresses 5 chronic conditions: diabetes, hypertension, weight management, musculoskeletal, and behavioral health.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n80% of new contracts signed in 2025 are for multi-condition programs.\n\u003c\/li\u003e\n\u003cli\u003e\nNew customer launches representing 107,000 lives covered reinforce B2B2C momentum.\n\u003c\/li\u003e\n\u003cli\u003e\nDemonstrated outcomes include an estimated $5,077 annual payer savings per user.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nDario addresses 5 chronic conditions, surpassing competitors that typically cover 1–3 conditions.\n\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nIntegration of features across 5 conditions requires time and user testing.\n\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nCommercial alignment is evidenced by client selection data.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nOver 70% of Dario's pipeline is for multi-condition programs.\n\u003c\/li\u003e\n\u003cli\u003e\n80% of new contracts in 2025 are for multi-condition programs.\n\u003c\/li\u003e\n\u003cli\u003e\nThe total client base reached 83 as of year-end 2024, with a forecast of 50% net client growth in 2025.\n\u003c\/li\u003e\n\u003cli\u003e\nThe Company secured 79 new employer clients year-to-date in 2025, exceeding the target of 40 by 98%.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\nThe current differentiator is strong due to the multi-condition offering.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eDarioHealth Corp. (DRIO) - VRIO Analysis: 3. Clinically Validated, Claims-Based ROI Evidence\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProvides proof payers demand, showing tangible cost reduction, like a \u003cstrong\u003e23%\u003c\/strong\u003e lower hospitalization rate and \u003cstrong\u003e26%\u003c\/strong\u003e lower all-cause charges in a recent study published in the Journal of Medical Internet Research (JMIR). Additional demonstrated outcomes include a \u003cstrong\u003e1.4%\u003c\/strong\u003e eHbA1c reduction and an average of \u003cstrong\u003e$5,000\u003c\/strong\u003e in annual payer savings per user.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eObserved Reduction\/Amount\u003c\/th\u003e\n\u003cth\u003eStudy Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitalization Rate\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e23%\u003c\/strong\u003e lower\u003c\/td\u003e\n\u003ctd\u003eIndependent, real-world claims analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAll-Cause Charges\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e26%\u003c\/strong\u003e lower\u003c\/td\u003e\n\u003ctd\u003eIndependent, real-world claims analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eeHbA1c\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1.4%\u003c\/strong\u003e reduction\u003c\/td\u003e\n\u003ctd\u003eClinical outcomes cited\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Payer Savings\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$5,000\u003c\/strong\u003e per user\u003c\/td\u003e\n\u003ctd\u003eClaims data suggested savings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e30-Day Hospital Readmission Rate (T2D)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e36%\u003c\/strong\u003e reduction\u003c\/td\u003e\n\u003ctd\u003eResearch presented by Sanofi U.S.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh. Independent, peer-reviewed medical claims analysis proving ROI is a high bar few digital health firms clear.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh. Competitors can run studies, but achieving the same rigor and positive results, like the \u003cstrong\u003e1.4%\u003c\/strong\u003e eHbA1c reduction seen and the \u003cstrong\u003e23%\u003c\/strong\u003e lower hospitalization rate, is difficult.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eYes. Management is using this evidence to drive adoption, as seen by the pipeline growth to \u003cstrong\u003e$69 million\u003c\/strong\u003e. The company has reached \u003cstrong\u003e79\u003c\/strong\u003e clients signed year-to-date, exceeding its 2025 target of \u003cstrong\u003e40\u003c\/strong\u003e new clients by \u003cstrong\u003e98%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCommercial Pipeline: \u003cstrong\u003e$69 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e2025 Client Target Exceeded: \u003cstrong\u003e79\u003c\/strong\u003e clients signed vs. target of \u003cstrong\u003e40\u003c\/strong\u003e (\u003cstrong\u003e98%\u003c\/strong\u003e over target)\u003c\/li\u003e\n\u003cli\u003eRevenue Recognition for Recent Wins: Expected to begin in Q1 2026\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained. Once validated by major payers, this evidence becomes a powerful, hard-to-replicate sales tool, underpinning commercial momentum.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eDarioHealth Corp. (DRIO) - VRIO Analysis: 4. High-Margin Recurring Revenue Structure\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The shift to B2B2C contracts ensures predictable revenue quality, with the core channel sustaining \u003cstrong\u003e80%+ non-GAAP gross margins\u003c\/strong\u003e since the first quarter of 2024.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2025\u003c\/th\u003e\n\u003cth\u003eQ3 2024\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e60%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e52%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore B2B2C Non-GAAP Gross Margin\u003c\/td\u003e\n\u003ctd\u003eSustaining \u003cstrong\u003e80%+\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e83%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many digital health firms struggle with low-margin or one-time revenue; this high-margin SaaS-like structure is better than average.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Temporary. Competitors are trying to shift to ARR, but achieving \u003cstrong\u003e60% GAAP gross margin\u003c\/strong\u003e, as seen in Q3 2025, is a challenge.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The entire commercial strategy is built around securing these high-quality, long-term contracts. The organization has exceeded its 2025 goal for new signings.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eExceeded 2025 goal of \u003cstrong\u003e40\u003c\/strong\u003e new signed accounts for 2026 revenue, with \u003cstrong\u003e45\u003c\/strong\u003e new signed accounts to date.\u003c\/li\u003e\n\u003cli\u003ePipeline of commercial opportunities expanded to \u003cstrong\u003e$69 million\u003c\/strong\u003e for 2026.\u003c\/li\u003e\n\u003cli\u003eMore than \u003cstrong\u003e50%\u003c\/strong\u003e of Company's new clients are choosing the multi-condition offering.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s a strong current advantage, but the market rewards this model, so others will chase it.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eDarioHealth Corp. (DRIO) - VRIO Analysis: 5. Proven B2B2C Commercial Execution \u0026amp; Client Acquisition\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSigning \u003cstrong\u003e79\u003c\/strong\u003e clients year-to-date, exceeding the 2025 goal of \u003cstrong\u003e40\u003c\/strong\u003e new clients by \u003cstrong\u003e98%\u003c\/strong\u003e. Total client base at the end of 2024 was \u003cstrong\u003e83\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eClient renewal rate maintained above \u003cstrong\u003e90%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eB2B2C recurring revenues for the twelve months ended December 31, 2024, were \u003cstrong\u003e$20.0 million\u003c\/strong\u003e, representing an increase of \u003cstrong\u003e300%\u003c\/strong\u003e compared to \u003cstrong\u003e$5 million\u003c\/strong\u003e in the twelve months ended December 31, 2023.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe organization demonstrated strong execution through channel partners, evidenced by the following commercial metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Clients End of 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e83\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEnd of 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Clients Signed YTD\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e79\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear-to-Date (as of December 2, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 New Client Goal\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e40\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2025 Forecast\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClient Renewal Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;90%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eB2B2C Recurring Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ4 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eB2B2C Recurring Revenue YoY Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e398%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ4 2024 vs Q4 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eeHbA1c Reduction\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eClinical Outcome\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer ROI\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5x\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eClinical Outcome\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTrailing Twelve Month Revenue as of September 30, 2025, was \u003cstrong\u003e$24.7M\u003c\/strong\u003e. Market Capitalization as of November 11, 2025, was \u003cstrong\u003e$82.2M\u003c\/strong\u003e. Operating Margin (TTM) was \u003cstrong\u003e-160.77%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eDarioHealth Corp. (DRIO) - VRIO Analysis: 6. Strategic Channel Partner Network\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Partnerships, like the one with a national benefit plan administrator, unlock distribution channels like TPAs, accelerating market access beyond direct sales. Initial clients under the national benefit administrator partnership began contributing to recurring revenues since \u003cstrong\u003eJanuary 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. The partnership with a leading national benefit plan administrator is noted as Dario's \u003cstrong\u003efirst\u003c\/strong\u003e national benefit administrator partnership.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Temporary. These relationships are built over time; a competitor would need to start from scratch to build similar trust.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The company explicitly credits its 'one-to-many channel partner strategy' for recent client wins. For example, \u003cstrong\u003e34 new employer clients\u003c\/strong\u003e signed in the past two weeks (as of December 2, 2025) are a testament to this strategy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It provides a faster path to scale now, but these partners may work with multiple vendors later.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Metric\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue Driver\u003c\/td\u003e\n\u003ctd\u003eDistribution Channel Expansion\u003c\/td\u003e\n\u003ctd\u003eRecurring revenues from B2B2C channel (employers and health plans) grew \u003cstrong\u003e300%\u003c\/strong\u003e year-over-year for full-year 2024, reaching \u003cstrong\u003e$20.0 million\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity Indicator\u003c\/td\u003e\n\u003ctd\u003eFoundational Partnership\u003c\/td\u003e\n\u003ctd\u003eThe national benefit administrator partnership is the company's \u003cstrong\u003efirst\u003c\/strong\u003e of its kind.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability Barrier\u003c\/td\u003e\n\u003ctd\u003eRelationship Building Time\u003c\/td\u003e\n\u003ctd\u003eCompetitors face the need to build similar trust from scratch.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization Evidence\u003c\/td\u003e\n\u003ctd\u003eStrategy Validation\u003c\/td\u003e\n\u003ctd\u003eThe 'one-to-many channel partner strategy' was credited for \u003cstrong\u003e34 new employer clients\u003c\/strong\u003e signed in a two-week period (as of Dec 2, 2025).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage Status\u003c\/td\u003e\n\u003ctd\u003eTime-Based Lead\u003c\/td\u003e\n\u003ctd\u003eThe channel provides a faster path to scale now. The B2B2C channel secured \u003cstrong\u003e36 new client wins\u003c\/strong\u003e in 2024, bringing the total client base to \u003cstrong\u003e83\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe success of the channel strategy is evidenced by the growth in the B2B2C segment:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eB2B2C, employers and health plans recurring revenues for the second quarter of 2024 totaled \u003cstrong\u003e$5.5 million\u003c\/strong\u003e, an increase of \u003cstrong\u003e315%\u003c\/strong\u003e year over year.\u003c\/li\u003e\n\u003cli\u003eThe company signed \u003cstrong\u003e45 new signed accounts to date\u003c\/strong\u003e (as of November 13, 2025), exceeding the 2025 goal of \u003cstrong\u003e40 new signed accounts for 2026 revenue\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe total client count reached \u003cstrong\u003e97\u003c\/strong\u003e as of the first quarter of 2025, up from \u003cstrong\u003e83\u003c\/strong\u003e at the end of 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eDarioHealth Corp. (DRIO) - VRIO Analysis: 7. Operational Efficiency \u0026amp; Cost Reduction Track Record\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Strong operational discipline has led to significant cost savings. Operating expenses were reduced by \u003cstrong\u003e31%\u003c\/strong\u003e for the first nine months of 2025 compared to the same period in 2024, representing a reduction of \u003cstrong\u003e$17.1 million\u003c\/strong\u003e,.\u003c\/p\u003e\n\u003cp\u003eThe operational efficiency is further detailed by period comparisons:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePeriod Comparison\u003c\/th\u003e\n\u003cth\u003eOperating Expenses (GAAP)\u003c\/th\u003e\n\u003cth\u003eChange ($)\u003c\/th\u003e\n\u003cth\u003eChange (%)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNine Months Ended Sept 30, 2025 vs. 2024\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$38.0 million\u003c\/strong\u003e vs. \u003cstrong\u003e$55.1 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$17.1 million\u003c\/strong\u003e decrease\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e31%\u003c\/strong\u003e decrease\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThree Months Ended Sept 30, 2025 vs. 2024\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$12.5 million\u003c\/strong\u003e vs. \u003cstrong\u003e$15.9 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$3.4 million\u003c\/strong\u003e decrease\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e21%\u003c\/strong\u003e decrease\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company anticipates a further \u003cstrong\u003e10%–15%\u003c\/strong\u003e reduction in operating expenses.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. The disciplined reduction is notable, especially as it is being achieved while implementing an \u003cstrong\u003eAI transformation\u003c\/strong\u003e to drive further efficiencies,.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Temporary. Competitors can cut costs, but achieving these specific reductions while maintaining product quality and expanding platform offerings is tough.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The focus on efficiency is clear, setting a path to cashflow breakeven by \u003cstrong\u003elate 2026 to early 2027\u003c\/strong\u003e,,,. This path is supported by high gross margins on the core business.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGAAP gross margin reached \u003cstrong\u003e60%\u003c\/strong\u003e for the nine months ended September 30, 2025,.\u003c\/li\u003e\n\u003cli\u003eNon-GAAP gross margins on the core B2B2C business sustained \u003cstrong\u003e80%+\u003c\/strong\u003e for 7 consecutive quarters as of Q3 2025,.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. This is a necessary step toward sustainability, not a unique barrier to entry.\u003c\/p\u003e\n\u003cp\u003eKey operational metrics supporting the efficiency drive include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eAI-driven process optimization\u003c\/strong\u003e is anticipated to provide additional efficiencies.\u003c\/li\u003e\n\u003cli\u003eThe company is executing a transition to a high-margin recurring revenue model built on high-quality, long-term contracts.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e45 new clients\u003c\/strong\u003e signed year-to-date (as of November 2025), exceeding the 2025 goal of 40,.\u003c\/li\u003e\n\u003cli\u003eMore than \u003cstrong\u003e50%\u003c\/strong\u003e of new clients are choosing the multi-condition offering,.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eDarioHealth Corp. (DRIO) - VRIO Analysis: 8. Specialized GLP-1 Lifecycle Management Solution\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAddresses a critical market need where discontinuation rates for GLP-1 RA therapy within one year range from \u003cstrong\u003e46%\u003c\/strong\u003e for patients with Type 2 Diabetes (T2D) to \u003cstrong\u003e65%\u003c\/strong\u003e for those without T2D. Dario’s platform supports sustained outcomes, as research showed users who discontinued GLP-1 medication maintained stable outcomes for at least \u003cstrong\u003esix (6) months\u003c\/strong\u003e post-discontinuation.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAmong continued GLP-1 users engaging with Dario's platform, average eA1c dropped from \u003cstrong\u003e9.0%\u003c\/strong\u003e to \u003cstrong\u003e6.7%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e31%\u003c\/strong\u003e of Dario members with Type 2 diabetes experienced blood glucose levels reflecting diabetes remission (A1c less than \u003cstrong\u003e6.5%\u003c\/strong\u003e) during a three-month period.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e70%\u003c\/strong\u003e of Dario members achieved a blood glucose level of less than \u003cstrong\u003e140 mg\/dL\u003c\/strong\u003e in their last month of usage maintained it for a three-month period.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIntegrating comprehensive behavioral support directly into the GLP-1 journey is a specific, high-value offering in a market where GLP-1 drugs accounted for \u003cstrong\u003e10.5%\u003c\/strong\u003e of total claims in \u003cstrong\u003e2025\u003c\/strong\u003e, up from \u003cstrong\u003e6.9%\u003c\/strong\u003e in \u003cstrong\u003e2023\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary, as the GLP-1 market grows, but Dario has an early mover advantage supported by a decade of data-driven insights.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eYes, integration is demonstrated through commercial momentum and platform capabilities. The Company secured \u003cstrong\u003e10\u003c\/strong\u003e new clients in Q3 2024. Dario anticipates a \u003cstrong\u003e38%\u003c\/strong\u003e reduction in total operating expenses between Q1 2024 and Q1 2025, contributing to an expected \u003cstrong\u003e49%\u003c\/strong\u003e reduction in operating losses by Q1 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary, as this feature is becoming increasingly necessary for maximizing return on investment for costly medications. Employers report that \u003cstrong\u003e59%\u003c\/strong\u003e of those covering GLP-1s for weight loss saw usage exceed projections.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eDarioHealth Specific Data\u003c\/th\u003e\n\u003cth\u003eGLP-1 Market\/Discontinuation Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e1-Year Discontinuation Rate (General)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e53.6%\u003c\/strong\u003e (Overall)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1-Year Discontinuation Rate (T2D)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e46%\u003c\/strong\u003e to \u003cstrong\u003e46.5%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1-Year Discontinuation Rate (Non-T2D)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e64.8%\u003c\/strong\u003e to \u003cstrong\u003e65%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eeA1c Reduction (Dario GLP-1 Users)\u003c\/td\u003e\n\u003ctd\u003eFrom \u003cstrong\u003e9.0%\u003c\/strong\u003e to \u003cstrong\u003e6.7%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSustained Outcomes Post-Discontinuation (Dario)\u003c\/td\u003e\n\u003ctd\u003eStable for at least \u003cstrong\u003esix (6) months\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployer GLP-1 Coverage (Firms $\\ge$ 5,000)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e43%\u003c\/strong\u003e in 2025, up from \u003cstrong\u003e28%\u003c\/strong\u003e previous year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGLP-1 Share of Claims (2025 Est.)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage BMI Reduction (Dario)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10%\u003c\/strong\u003e average\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDario Platform Retention Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e80%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eDarioHealth Corp. (DRIO) - VRIO Analysis: 9. Large-Scale User Base \u0026amp; Platform Engagement\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eA history with over 119,482 members analyzed in recent research provides a massive pool for data training and demonstrates inherent user-centric design that drives high satisfaction, evidenced by a 4.9\/5 Stars rating in the App Store.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eModerate. A large, established user base, with eligible users spanning millions worldwide as of 2024, in digital health is a significant asset for credibility and data.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eHigh. Acquiring that many users organically and maintaining high engagement, such as the 80% retention rate, is a massive hurdle for new entrants.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eYes. The platform is described as user-centric, suggesting the organization prioritizes the experience that keeps users active, with engagement improving 29% over two years in one study cohort.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eSustained. The network effect of data and the established user base create a durable foundation, with engagement increasing by 56% in another product experience test group.\u003c\/p\u003e\n\u003cp\u003eThe platform's scale and engagement metrics are further detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApp Store Rating\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4.9\/5\u003c\/strong\u003e Stars\u003c\/td\u003e\n\u003ctd\u003ePlatform Engagement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMember Retention Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e80%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMember Engagement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUsers Analyzed in Research\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e119,482\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDiabetes Outcome Study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEngagement Improvement (2-Year Study)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e29%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOver Two Years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEngagement Increase (New Experience)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e56%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to Baseline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003ePlatform utilization and financial backing support this scale:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe platform supports multiple chronic conditions, with 59% of clients leveraging the cardio-metabolic suite for hypertension management.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents on the balance sheet as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e, totaled \u003cstrong\u003e$31.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGAAP gross margin reached \u003cstrong\u003e60%\u003c\/strong\u003e in the third quarter of \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNon-GAAP gross margins on core B2B2C business have been \u003cstrong\u003e80%+\u003c\/strong\u003e for \u003cstrong\u003e7\u003c\/strong\u003e consecutive quarters.\u003c\/li\u003e\n\u003cli\u003eThe Company signed \u003cstrong\u003e45\u003c\/strong\u003e new clients year-to-date in \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: The draft 13-week cash view is pending, based on the latest reported cash balance of \u003cstrong\u003e$31.9 million\u003c\/strong\u003e as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516153192597,"sku":"drio-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/drio-vrio-analysis.png?v=1740165754","url":"https:\/\/dcf-model.com\/fr\/products\/drio-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}